undamentalytics Newsletter
Sign in

20/20 Biolabs, Inc. balance sheet

At the end of fiscal 2025, 20/20 Biolabs, Inc. had total assets of $4.1m, total liabilities of $4.2m and shareholders' equity of −$19,225. It held $1.0m in cash against $693,966 of debt: net cash of $332,021.

Balance sheet

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025
Cash and equivalents1,7841,026
Receivables135200
Inventory47116
Total current assets2,0341,471
Total assets3,5844,137
Accounts payable372869
Deferred revenue (current)470415
Total current liabilities1,3552,463
Long-term debt—619
Total debt0694
Total liabilities2,0794,157
Shareholders' equity1,505−19
Net debt (negative = net cash)−1,784−332
Shares outstanding5m5m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from 20/20 Biolabs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 20/20 Biolabs, Inc.